1192811-95-2Relevant articles and documents
Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship
Cook, James,Zusi, F. Christopher,McDonald, Ivar M.,King, Dalton,Hill, Matthew D.,Iwuagwu, Christiana,Mate, Robert A.,Fang, Haiquan,Zhao, Rulin,Wang, Bei,Cutrone, Jingfang,Ma, Baoqing,Gao, Qi,Knox, Ronald J.,Matchett, Michele,Gallagher, Lizbeth,Ferrante, Meredith,Post-Munson, Debra,Molski, Thaddeus,Easton, Amy,Miller, Regina,Jones, Kelli,Digavalli, Siva,Healy, Francine,Lentz, Kimberley,Benitex, Yulia,Clarke, Wendy,Natale, Joanne,Siuciak, Judith A.,Lodge, Nicholas,Zaczek, Robert,Denton, Rex,Morgan, Daniel,Bristow, Linda J.,Macor, John E.,Olson, Richard E.
supporting information, p. 11171 - 11181 (2016/12/30)
The design and synthesis of a series of quinuclidine-containing spirooxazolidines ("spiroimidates") and their utility as α7 nicotinic acetylcholine receptor partial agonists are described. Selected members of the series demonstrated excellent selectivity
QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
-
Page/Page column 76, (2011/05/11)
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
